Cargando…

Jacareubin inhibits TLR4-induced lung inflammatory response caused by the RBD domain of SARS-CoV-2 Spike protein

BACKGROUND: COVID-19, the disease caused by SARS-CoV-2 virus infection, has been a major public health problem worldwide in the last 2 years. SARS-CoV-2-dependent activation of innate immune receptors contributes to the strong local and systemic inflammatory reaction associated with rapid disease ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Segura-Villalobos, Deisy, Roa-Velázquez, Daniela, Zavala-Vargas, Dan I., Filisola-Villaseñor, Jessica G., Castillo Arellano, Jorge Ivan, Morales Ríos, Edgar, Reyes-Chilpa, Ricardo, González-Espinosa, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9362068/
https://www.ncbi.nlm.nih.gov/pubmed/35930194
http://dx.doi.org/10.1007/s43440-022-00398-5
_version_ 1784764649515778048
author Segura-Villalobos, Deisy
Roa-Velázquez, Daniela
Zavala-Vargas, Dan I.
Filisola-Villaseñor, Jessica G.
Castillo Arellano, Jorge Ivan
Morales Ríos, Edgar
Reyes-Chilpa, Ricardo
González-Espinosa, Claudia
author_facet Segura-Villalobos, Deisy
Roa-Velázquez, Daniela
Zavala-Vargas, Dan I.
Filisola-Villaseñor, Jessica G.
Castillo Arellano, Jorge Ivan
Morales Ríos, Edgar
Reyes-Chilpa, Ricardo
González-Espinosa, Claudia
author_sort Segura-Villalobos, Deisy
collection PubMed
description BACKGROUND: COVID-19, the disease caused by SARS-CoV-2 virus infection, has been a major public health problem worldwide in the last 2 years. SARS-CoV-2-dependent activation of innate immune receptors contributes to the strong local and systemic inflammatory reaction associated with rapid disease evolution. The receptor-binding domain (RBD) of Spike (S) viral protein (S-RBD) is essential for virus infection and its interacting molecules in target cells are still under identification. On the other hand, the search for accessible natural molecules with potential therapeutic use has been intense and remains an active field of investigation. METHODS: C57BL6/J (control) and Toll-like receptor (TLR) 4-deficient (Lps del) mice were nebulized with recombinant S-RBD. Tumor Necrosis Factor-alpha (TNF-α) and Interleukin (IL)-6 production in bronchoalveolar lavages (BALs) was determined by enzyme-linked immunosorbent assay (ELISA). Lung-infiltrating cells recovered in BALs were quantified by hematoxylin–eosin (H&E) stain. In selected groups of animals, the natural compound Jacareubin or dexamethasone were intraperitoneally (ip) administered 2 hours before nebulization. RESULTS: A rapid lung production of TNF-α and IL-6 and cell infiltration was induced by S-RBD nebulization in control but not in Lps del mice. Pre-treatment with Jacareubin or dexamethasone prevented S-RBD-induced TNF-α and IL-6 secretion in BALs from control animals. CONCLUSIONS: S-RBD domain promotes lung TNF-α and IL-6 production in a TLR4-dependent fashion in C57BL6/J mice. Xanthone Jacareubin possesses potential anti-COVID-19 properties that, together with the previously tested anti-inflammatory activity, safety, and tolerance, make it a valuable drug to be further investigated for the treatment of cytokine production caused by SARS-CoV-2 infection. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s43440-022-00398-5.
format Online
Article
Text
id pubmed-9362068
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-93620682022-08-10 Jacareubin inhibits TLR4-induced lung inflammatory response caused by the RBD domain of SARS-CoV-2 Spike protein Segura-Villalobos, Deisy Roa-Velázquez, Daniela Zavala-Vargas, Dan I. Filisola-Villaseñor, Jessica G. Castillo Arellano, Jorge Ivan Morales Ríos, Edgar Reyes-Chilpa, Ricardo González-Espinosa, Claudia Pharmacol Rep Special Issue: Short Communication BACKGROUND: COVID-19, the disease caused by SARS-CoV-2 virus infection, has been a major public health problem worldwide in the last 2 years. SARS-CoV-2-dependent activation of innate immune receptors contributes to the strong local and systemic inflammatory reaction associated with rapid disease evolution. The receptor-binding domain (RBD) of Spike (S) viral protein (S-RBD) is essential for virus infection and its interacting molecules in target cells are still under identification. On the other hand, the search for accessible natural molecules with potential therapeutic use has been intense and remains an active field of investigation. METHODS: C57BL6/J (control) and Toll-like receptor (TLR) 4-deficient (Lps del) mice were nebulized with recombinant S-RBD. Tumor Necrosis Factor-alpha (TNF-α) and Interleukin (IL)-6 production in bronchoalveolar lavages (BALs) was determined by enzyme-linked immunosorbent assay (ELISA). Lung-infiltrating cells recovered in BALs were quantified by hematoxylin–eosin (H&E) stain. In selected groups of animals, the natural compound Jacareubin or dexamethasone were intraperitoneally (ip) administered 2 hours before nebulization. RESULTS: A rapid lung production of TNF-α and IL-6 and cell infiltration was induced by S-RBD nebulization in control but not in Lps del mice. Pre-treatment with Jacareubin or dexamethasone prevented S-RBD-induced TNF-α and IL-6 secretion in BALs from control animals. CONCLUSIONS: S-RBD domain promotes lung TNF-α and IL-6 production in a TLR4-dependent fashion in C57BL6/J mice. Xanthone Jacareubin possesses potential anti-COVID-19 properties that, together with the previously tested anti-inflammatory activity, safety, and tolerance, make it a valuable drug to be further investigated for the treatment of cytokine production caused by SARS-CoV-2 infection. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s43440-022-00398-5. Springer International Publishing 2022-08-05 2022 /pmc/articles/PMC9362068/ /pubmed/35930194 http://dx.doi.org/10.1007/s43440-022-00398-5 Text en © The Author(s) under exclusive licence to Maj Institute of Pharmacology Polish Academy of Sciences 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Special Issue: Short Communication
Segura-Villalobos, Deisy
Roa-Velázquez, Daniela
Zavala-Vargas, Dan I.
Filisola-Villaseñor, Jessica G.
Castillo Arellano, Jorge Ivan
Morales Ríos, Edgar
Reyes-Chilpa, Ricardo
González-Espinosa, Claudia
Jacareubin inhibits TLR4-induced lung inflammatory response caused by the RBD domain of SARS-CoV-2 Spike protein
title Jacareubin inhibits TLR4-induced lung inflammatory response caused by the RBD domain of SARS-CoV-2 Spike protein
title_full Jacareubin inhibits TLR4-induced lung inflammatory response caused by the RBD domain of SARS-CoV-2 Spike protein
title_fullStr Jacareubin inhibits TLR4-induced lung inflammatory response caused by the RBD domain of SARS-CoV-2 Spike protein
title_full_unstemmed Jacareubin inhibits TLR4-induced lung inflammatory response caused by the RBD domain of SARS-CoV-2 Spike protein
title_short Jacareubin inhibits TLR4-induced lung inflammatory response caused by the RBD domain of SARS-CoV-2 Spike protein
title_sort jacareubin inhibits tlr4-induced lung inflammatory response caused by the rbd domain of sars-cov-2 spike protein
topic Special Issue: Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9362068/
https://www.ncbi.nlm.nih.gov/pubmed/35930194
http://dx.doi.org/10.1007/s43440-022-00398-5
work_keys_str_mv AT seguravillalobosdeisy jacareubininhibitstlr4inducedlunginflammatoryresponsecausedbytherbddomainofsarscov2spikeprotein
AT roavelazquezdaniela jacareubininhibitstlr4inducedlunginflammatoryresponsecausedbytherbddomainofsarscov2spikeprotein
AT zavalavargasdani jacareubininhibitstlr4inducedlunginflammatoryresponsecausedbytherbddomainofsarscov2spikeprotein
AT filisolavillasenorjessicag jacareubininhibitstlr4inducedlunginflammatoryresponsecausedbytherbddomainofsarscov2spikeprotein
AT castilloarellanojorgeivan jacareubininhibitstlr4inducedlunginflammatoryresponsecausedbytherbddomainofsarscov2spikeprotein
AT moralesriosedgar jacareubininhibitstlr4inducedlunginflammatoryresponsecausedbytherbddomainofsarscov2spikeprotein
AT reyeschilparicardo jacareubininhibitstlr4inducedlunginflammatoryresponsecausedbytherbddomainofsarscov2spikeprotein
AT gonzalezespinosaclaudia jacareubininhibitstlr4inducedlunginflammatoryresponsecausedbytherbddomainofsarscov2spikeprotein